Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
2.090
-0.070 (-3.24%)
At close: Nov 20, 2024, 4:00 PM
2.000
-0.090 (-4.31%)
Pre-market: Nov 21, 2024, 6:48 AM EST
Incannex Healthcare Revenue
Incannex Healthcare had revenue of $74.00K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $86.00K, down -86.86% year-over-year. In the fiscal year ending June 30, 2024, Incannex Healthcare had annual revenue of $12.00K.
Revenue (ttm)
$86.00K
Revenue Growth
-86.86%
P/S Ratio
n/a
Revenue / Employee
$9,556
Employees
9
Market Cap
36.87M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIXHL News
- 6 days ago - Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) - Newsfile Corp
- 7 weeks ago - Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives - Newsfile Corp
- 3 months ago - FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed - GlobeNewsWire
- 4 months ago - Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X - GlobeNewsWire
- 6 months ago - Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea - GlobeNewsWire